Urticarial Vasculitis After First Denosumab Injection in an Osteoporotic Woman Diagnosed with Cushing's Syndrome

ÖZBEK EREN İ., ŞEKER A., YAVUZ D.

TURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM, vol.26, no.3, pp.181-183, 2022 (ESCI, Scopus, TRDizin) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 26 Issue: 3
  • Publication Date: 2022
  • Doi Number: 10.5152/tjem.2022.22012
  • Journal Name: TURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.181-183
  • Keywords: Denosumab, osteoporosis, urticarial, vasculitis, CUTANEOUS DRUG-REACTIONS, POSTMENOPAUSAL WOMEN, BONE TURNOVER, ALENDRONATE, REDUCTION, MASS
  • Marmara University Affiliated: Yes

Abstract

Denosumab is a human-derived monoclonal immunoglobulin G2 antibody against the receptor activator of nuclear factor kappa B ligand, inhibiting the differentiation and function of osteoclast precursor cells by its antiosteoclastic action. Denosumab is approved for postmenopausal, glucocorti coid-induced, and male osteoporozis with high risk of fracture. The use of denosumab has increased in recent years. While new medications continue to be developed, the number of agents causing drug-induced vasculitis is expected to increase. It may be a good strategy to identify risk factors for vasculitis development and look for these factors before drug administration. Here, we present a rare complication of denosumab, urticarial vasculitis, after the first denosumab injection in an osteoporotic woman diagnosed with Cushing's syndrome.